JPRN-jRCT2080220011未知3 期
Phase 3 study of EPOCH to maintain hemoglobin levels in hemodialysis patients
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.20 years - 80 years of age
- •2.hemoglobin between 9.0 g/dl to 12.0 g/dl
- •3.serum ferritin level and over 100 ng/ml or transferrin saturation and over 20%
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
TRIUMPH A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patientspaaroxysmal nocturnal hemoglobinuriaMedDRA version: 6.1Level: PTClassification code 10034042EUCTR2004-000646-20-ITALEXION PHARMACEUTICALS INC75
进行中（未招募）
不适用
A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients - TRIUMPHparoxysmal nocturnal hemoglobinuriaMedDRA version: 7.0Level: PTClassification code 10034042EUCTR2004-000646-20-SEALEXION PHARMACEUTICALS INCORPORATED75
进行中（未招募）
1 期
A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients - TRIUMPHEUCTR2004-000646-20-IEALEXION PHARMACEUTICALS INCORPORATED75
进行中（未招募）
1 期
A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients - TRIUMPHEUCTR2004-000646-20-GBALEXION PHARMACEUTICALS INCORPORATED109
进行中（未招募）
1 期
Study to evaluate long term effect of an experimental approach of gene therapy to treat ß-thalassemia major, know also as transfusion dependent ß-thalassemia, and the sickle cell disease.Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-ITBLUEBIRD BIO, INC.94